119
Views
0
CrossRef citations to date
0
Altmetric
PERSPECTIVES

Clevidipine and COVID 19: From Hypertension to Inflammatory Response

&
Pages 2383-2386 | Published online: 13 Apr 2022

References

  • Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-7
  • Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473. doi:10.1016/S0140-6736(20)30185-9
  • World Health Organization. International Health Regulations Emergency Committee on Novel Coronavirus in China. Available from: https://www.who.int/news-room/events/detail/2020/01/30/default-calendar/international-health-regulationsemergency-committee-on-novel-coronavirus-in-china. Accessed May 17, 2020.
  • World Health Organization. WHO director-general’s opening remarks at the media briefing on COVID-19–11 March 2020. Available From: https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefingon-covid-19–11-march-2020. Accessed May 17, 2020.
  • Chen Y, Klein SL, Garibaldi BT, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. doi:10.1016/j.arr.2020.101205
  • Schiffrin EL, Flack JM, Ito S, Muntner P, Webb RC. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373–374. doi:10.1093/ajh/hpaa057
  • Tadic M, Cuspidi C, Mancia G, Dell’Oro R, Grassi G. COVID-19 hypertension and cardiovascular diseases: should we change the therapy? Pharmacol Res. 2020;158:104906. doi:10.1016/j.phrs.2020.104906
  • Matarese A, Gambardella J, Sardu C, Santulli G. miR-98 regulates TMPRSS2 expression in human endothelial cells: key implications for COVID-19. Biomedicines. 2020;8(11):462. doi:10.3390/biomedicines8110462
  • D’Onofrio N, Scisciola L, Sardu C, et al. ACE2 receptor in diabetes: open door for SARS-COV-2 entry in cardiomyocyte. Cardiovasc Diabetol. 2021;20(1):99. doi:10.1186/s12933-021-01286-7
  • Sardu C, Maggi P, Messina V, et al. Drug therapy affect the clinical prognosis of hypertensive patients with COVID-19 infection? Data from centers of Southern Italy. J Am Heart Assoc. 2020;9(17):e016948. doi:10.1161/JAHA.120.016948
  • Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by COVID-19: can we do more on glycemic control? Diabetes Care. 2020;43(7):1408–1415. doi:10.2337/dc20-0723
  • Figliozzi S, Masci PG, Ahmadi N, et al. Predictors of adverse prognosis in COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50(10):e13362. doi:10.1111/eci.13362
  • Nguyen HM, Ma K, Pham DQ. Clevidipine for the treatment of severe hypertension in adults. Clin Ther. 2010;32(1):11–23. doi:10.1016/j.clinthera.2010.01.025
  • Marfella R, Paolisso P, Sardu C, et al. colonizes coronary thrombus and impairs heart microcirculation bed in asymptomatic SARS-CoV-2 positive subjects with acute myocardial infarction. Crit Care. 2021;25(1):217. doi:10.1186/s13054-021-03643-0
  • Petrovic V, Radenkovic D, Radenkovic G, Djordjevic V, Banach M. Pathophysiology of cardiovascular complications in COVID-19. Front Physiol. 2020;11:575600. doi:10.3389/fphys.2020.575600
  • Modin D, Claggett B, Sindet-Pedersen C, et al. Acute COVID-19 and the incidence of ischemic stroke and acute myocardial infarction. Circulation. 2020;142:2080–2082. doi:10.1161/CIRCULATIONAHA.120.050809
  • Ericsson H, Fakt C, Mellgård JA, et al. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers. Br J Clin Pharmacol. 1999;47:531–538. doi:10.1046/j.1365-2125.1999.00933.x
  • Kotrly KJ, Ebert TJ, Vucins E, Igler FO, Barney JA, Kampine JP. Baroreceptor reflex control of heart rate during isoflurane anesthesia in humans. Anesthesiology. 1984;60:173–179. doi:10.1097/00000542-198403000-00001
  • keating GM. Clevidipine: a review of its use for managing blood pressure in perioperative and intensive care settings. Drugs. 2014;74(16):1947–1960. doi:10.1007/s40265-014-0313-6
  • Anka AU, Tahir MI, Abubakar SD, et al. Coronavirus disease 2019 (COVID-19): an overview of the immunopathology, serological diagnosis and management. Scand J Immunol. 2021;93(4):e12998. doi:10.1111/sji.12998
  • Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21(2):167–179. doi:10.1007/s10238-020-00671-y
  • Muller SH, Diaz JH, Kaye AD. Intralipid emulsion rescue therapy: emerging therapeutic indications in medical practice. J La State Med Soc. 2016;168(3):101–103.
  • Sayed S, Idriss NK, Sayyedf HG, et al. Effects of propofol and isoflurane on haemodynamics and the inflammatory response in cardiopulmonary bypass surgery. Br J Biomed Sci. 2015;72(3):93–101. doi:10.1080/09674845.2015.11666803
  • Ulici A, Jancik J, Lam TS, et al. Clevidipine versus sodium nitroprusside in acute aortic dissection: a retrospective chart review. Am J Emerg Med. 2017;35:1514–1518. doi:10.1016/j.ajem.2017.06.030
  • Alviar CL, Gutierrez A, Cho L, Krishnaswamy A, Saleh A, Lincoff A. Clevidipine as a therapeutic and cost- effective alternative to sodium nitroprusside in patients with acute aortic dissection. Eur Hear J Acute Cardiovasc Care. 2017;9:S5–S12.
  • Pagnesi M, Baldetti L, Beneduce A, et al. Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19. Heart. 2020;106(17):1324–1331.